Article
Oncology
Rachel J. Keogh, Razia Aslam, Maeve A. Hennessy, Zac Coyne, Bryan T. Hennessy, Oscar S. Breathnach, Liam Grogan, Patrick G. Morris
Summary: This retrospective study at a National Neuro-Oncology center investigated the tolerability of PCV chemotherapy in routine clinical practice and found that few patients could complete all 6 cycles of treatment with common hematological toxicities observed. It may be preferable to adjust chemotherapy doses from the start or consider alternative treatment, especially in older patients with LGG.
Article
Oncology
Vincent Esteyrie, Caroline Dehais, Elodie Martin, Catherine Carpentier, Emmanuelle Uro-Coste, Dominique Figarella-Branger, Charlotte Bronniman, Damien Pouessel, Delphine Larrieu Ciron, Francois Ducray, Elizabeth Cohen-Jonathan Moyal
Summary: The study showed that, compared to RT + TMZ, RT + PCV significantly improved progression-free survival in patients with IDH-mutant anaplastic astrocytomas. However, the RT + TMZ regimen was better tolerated.
Article
Oncology
Stephen Ahn, Young Kim, Ja Shin, Jae-Sung Park, Changyoung Yoo, Youn Lee, Yong-Kil Hong, Sin-Soo Jeun, Seung Yang
Summary: Modified procarbazine and lomustine chemotherapy is a viable alternative for recurrent glioma with reduced toxicity and comparable clinical efficacy.
Article
Medicine, Research & Experimental
Guanglie Li, Xiwei Xu, Jianqi Cui, Fan Zhang, Siyang Wang
Summary: Recurrent high-grade glioma is a refractory disease with poor prognosis. Apatinib combined with temozolomide has been shown to improve efficacy and prolong survival in the treatment of recurrent high-grade gliomas. A meta-analysis of 10 studies involving 357 patients was conducted to further investigate the efficacy and prognosis of this treatment. The results indicated that apatinib combined with temozolomide had a significant overall objective response rate and disease control rate, with better outcomes observed in the dose-dense temozolomide subgroup.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2023)
Article
Oncology
Zhuang Kang, Shan Li, Xun Kang, Jing Deng, Huarong Yang, Feng Chen, Jiandong Jiang, Jie Zhang, Wenbin Li
Summary: This study aimed to evaluate the efficacy and safety of injectable chlorogenic acid (CGA) in patients with recurrent high-grade glioma. The results showed that CGA was well tolerated, with a maximum tolerated dose of 5.5 mg/kg. The most common adverse events occurred at the injection sites. Clinical pharmacokinetic study demonstrated rapid elimination of CGA from plasma, and after the first treatment cycle, 52.2% of patients achieved stable disease.
CANCER BIOLOGY & MEDICINE
(2023)
Article
Oncology
Andrew B. Lassman, Khe Hoang-Xuan, Mei-Yin C. Polley, Alba A. Brandes, J. Gregory Cairncross, Johan M. Kros, Lynn S. Ashby, Martin J. B. Taphoorn, Luis Souhami, Winand N. M. Dinjens, Nadia N. Laack, Mathilde C. M. Kouwenhoven, Karen L. Fink, Pim J. French, David R. Macdonald, Denis Lacombe, Minhee Won, Thierry Gorlia, Minesh P. Mehta, Martin J. van den Bent
Summary: This study reports the final long-term survival results of the European Organization for the Research and Treatment of Cancer 26951 and Radiation Therapy Oncology Group 9402 trials, comparing radiotherapy with and without PCV chemotherapy for anaplastic oligodendroglial tumors. The results show similar long-term survival rates even without tumor recurrence.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Health Care Sciences & Services
Fabiana Gregucci, Alessia Surgo, Roberta Carbonara, Letizia Laera, Maria Paola Ciliberti, Maria Annunziata Gentile, Morena Caliandro, Nicola Sasso, Ilaria Bonaparte, Vincenzo Fanelli, Romina Tortora, Eleonora Paulicelli, Giammarco Surico, Giuseppe Lombardi, Francesco Signorelli, Alba Fiorentino
Summary: The study evaluated the safety and efficacy of re-irradiation with radiosurgery or fractionated stereotactic radiotherapy in association with chemotherapy for recurrent high-grade gliomas. The results demonstrated that this treatment approach is safe and feasible for patients with recurrent HGG.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Oncology
Karan S. Dixit, Sean Sachdev, Christina Amidei, Priya Kumthekar, Tim J. Kruser, Vinai Gondi, Sean Grimm, Rimas Lukas, Martin Kelly Nicholas, Steven J. Chmura, Angela J. Fought, Minesh Mehta, Jeffrey J. Raizer
Summary: This study demonstrates that re-irradiation with bevacizumab and temozolomide is a safe and effective salvage treatment for patients with bevacizumab-refractory high-grade glioma. Patients further from their initial radiotherapy may derive greater benefit from this regimen.
JOURNAL OF NEURO-ONCOLOGY
(2021)
Article
Clinical Neurology
Hui Yao, Jiangang Liu, Chi Zhang, Yunxiang Shao, Xuetao Li, Ming Feng, Ximing Wang, Wenjuan Gan, Youxin Zhou, Yulun Huang
Summary: The study investigated the efficacy and safety of apatinib in combination with dose-dense regimens of temozolomide for treating recurrent high-grade glioma. Results showed a disease control rate of 82.3%, with a progression-free survival of 4 months and overall survival of 9.1 months. Apatinib and TMZ may be an alternative treatment option for patients with recurrent high-grade glioma, especially those with a low Karnofsky performance status. More studies with larger sample sizes are needed to confirm these findings.
JOURNAL OF CLINICAL NEUROSCIENCE
(2021)
Review
Biochemistry & Molecular Biology
Jacob P. Fisher, David C. Adamson
Summary: The standard of care for high-grade gliomas includes surgical resection, radiation therapy, and temozolomide, which have improved patient survival rates. Besides temozolomide, there are several other FDA-approved treatments for HGG, with tumor treatment fields being the only one shown to significantly improve survival rates.
Article
Oncology
J. Weller, N. Schaefer, C. Schaub, T. Tzaridis, T. Zeyen, M. Schneider, A. L. Potthoff, F. A. Giordano, J. P. Steinbach, P. S. Zeiner, T. Kowalski, M. Sabel, P. Hau, D. Krex, O. Grauer, R. Goldbrunner, O. Schnell, G. Tabatabai, F. Ringel, F. Schmidt-Graf, S. Brehmer, J. C. Tonn, L. Bullinger, P. Vajkoczy, M. Glas, H. Vatter, U. Herrlinger, C. Seidel
Summary: In the CeTeG/NOA-09 randomized phase III trial, TMZ/CCNU combination therapy was found to be superior to TMZ in newly diagnosed MGMT methylated glioblastoma, with higher incidence of hematotoxicity. This study analyzed high-grade hematotoxicity and its prognostic relevance in the trial population.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Review
Oncology
Maximilian J. Mair, Marjolein Geurts, Martin J. van den Bent, Anna S. Berghoff
Summary: WHO grade II-III gliomas are rare primary brain tumors with longer median survival compared to grade IV glioblastoma. Treatment involves maximal safe resection and adjuvant therapies, with challenges in conducting clinical trials due to rarity and long follow-up times. The 2016 WHO Classification introduced a molecular diagnostic framework for more homogenous subgroups. Available evidence for adjuvant treatment was generated pre-molecular era, emphasizing the need for further research in this field.
CANCER TREATMENT REVIEWS
(2021)
Review
Immunology
Payal Aggarwal, Wen Luo, Katherine C. C. Pehlivan, Hai Hoang, Prajwal Rajappa, Timothy P. P. Cripe, Kevin A. A. Cassady, Dean A. A. Lee, Mitchell S. S. Cairo
Summary: This article examines the differences and similarities between high grade gliomas in adults and children, including epidemiology, etiology, pathogenesis, and treatment approaches. Although there are differences in clinical presentation, molecular biology background, and response to chemotherapy, both types of gliomas respond to immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Jonathan P. S. Knisely, Howard A. Fine
Summary: The Oncology Grand Rounds series aims to provide clinical context to original reports published in the Journal. It includes case presentations, discussions on diagnostic and management challenges, literature reviews, and suggested management approaches by the authors. The goal is to help readers apply key study findings, including those from the Journal of Clinical Oncology, to their own clinical practice.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Yao Yu, Javier Villanueva-Meyer, Matthew R. Grimmer, Stephanie Hilz, David A. Solomon, Serah Choi, Michael Wahl, Tali Mazor, Chibo Hong, Anny Shai, Joanna J. Phillips, Bruce H. Wainer, Michael McDermott, Daphne Haas-Kogan, Jennie W. Taylor, Nicholas Butowski, Jennifer L. Clarke, Mitchel S. Berger, Annette M. Molinaro, Susan M. Chang, Joseph F. Costello, Nancy Ann Oberheim Bush
Summary: The study found that hypermutation induced by temozolomide greatly increased the risk of high-grade disease recurrence in low-grade IDH-mutant glioma patients previously treated with TMZ, and was associated with shorter survival after transformation. Tumors with hypermutation were more likely to develop discontiguous foci of disease in the brain and spine.
Review
Oncology
E. J. Bass, A. Pantovic, M. J. Connor, S. Loeb, A. R. Rastinehad, M. Winkler, Rhian Gabe, H. U. Ahmed
Summary: Using MRI-guided biopsy offers superior detection rates of clinically significant PCa and reduces the detection of insignificant PCa compared to TRUS-GB in patients with suspected prostate cancer. However, no individual MRI-GB technique was found to be better in detecting csPCa. Prospective adequately powered randomized controlled trials are needed for further validation.
PROSTATE CANCER AND PROSTATIC DISEASES
(2022)
Article
Respiratory System
Kamran Siddiqi, Ada Keding, Anna-Marie Marshall, Omara Dogar, Jinshuo Li, Rumana Huque, Razia Fatima, Amina Khan, Helen Elsey, Rhian Gabe, Daniel Kotz, Aziz Sheikh
Summary: Patients with TB who quit smoking during treatment may have better outcomes, including higher cure rates and lower relapse rates. Health professionals should offer support to help TB patients quit smoking for improved treatment outcomes.
Article
Oncology
Johnathan K. Joffe, Fay H. Cafferty, Laura Murphy, Gordon J. S. Rustin, Syed A. Sohaib, Rhian Gabe, Sally P. Stenning, Elizabeth James, Dipa Noor, Simona Wade, Francesca Schiavone, Sarah Swift, Elaine Dunwoodie, Marcia Hall, Anand Sharma, Jeremy Braybrooke, Jonathan Shamash, John Logue, Henry H. Taylor, Ivo Hennig, Jeff White, Sarah Rudman, Jane Worlding, David Bloomfield, Guy Faust, Hilary Glen, Rachel Jones, Michael Seckl, Graham MacDonald, Thiagarajan Sreenivasan, Satish Kumar, Andrew Protheroe, Ramachandran Venkitaraman, Danish Mazhar, Victoria Coyle, Martin Highley, Tom Geldart, Robert Laing, Richard S. Kaplan, Robert A. Huddart
Summary: The purpose of this study was to evaluate whether MRI or a reduced scan schedule could be used without increasing early relapse. The results showed that MRI can be recommended to reduce irradiation and a reduced scan schedule does not have adverse effects on long-term outcomes.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Editorial Material
Oncology
Frank Saran, David D. Eisenstat
Article
Radiology, Nuclear Medicine & Medical Imaging
Daniel Rodriguez, Raphael Calmon, Esther Sanchez Aliaga, Daniel Warren, Monika Warmuth-Metz, Chris Jones, Alan Mackay, Pascale Varlet, Marie-Cecile Le Deley, Darren Hargrave, Adela Canete, Maura Massimino, Amedeo A. Azizi, Frank Saran, Gudrun Zahlmann, Josep Garcia, Gilles Vassal, Jacques Grill, Andrew Peet, Robert A. Dineen, Paul S. Morgan, Timothy Jaspan
Summary: This study analyzed the MRI and molecular characteristics of Diffuse Midline Gliomas (DMG) and found that regardless of H3 K27 subtype, DMG involving the thalamus had poor outcomes. Participants who underwent major debulking or total or near-total resection had longer survival, and those without leptomeningeal metastatic dissemination had better outcomes.
Article
Biotechnology & Applied Microbiology
Scott Owen, Scheryll Alken, Jad Alshami, Marie -Christine Guiot, Petr Kavan, David A. Reardon, Thierry Muanza, Neil Gibson, Karine Pemberton, Flavio Solca, Agnieszka Cseh, Frank Saran
Summary: Glioblastoma is an aggressive tumor with EGFR aberrations observed in many cases. Afatinib may provide treatment benefit in patients with these genetic aberrations, but further studies are needed to identify potential beneficiaries.
ONCOTARGETS AND THERAPY
(2022)
Article
Oncology
Shuping J. Li, Tara Seedher, Linda D. Sharples, Sally C. Benton, Christopher Mathews, Rhian Gabe, Peter Sasieni, Stephen W. Duffy
Summary: This study analyzed data from the NHS Bowel Cancer Screening Programme and found that increasing the fecal hemoglobin (f-Hb) threshold was more efficient than increasing the interscreening interval in terms of reducing colonoscopy requirements and detecting colorectal cancer and other abnormalities.
BRITISH JOURNAL OF CANCER
(2022)
Article
Respiratory System
Philip A. J. Crosbie, Rhian Gabe, Irene Simmonds, Neil Hancock, Panos Alexandris, Martyn Kennedy, Suzanne Rogerson, David Baldwin, Richard Booton, Claire Bradley, Mike Darby, Claire Eckert, Kevin N. Franks, Jason Lindop, Sam M. Janes, Henrik Moller, Rachael L. Murray, Richard D. Neal, Samantha L. Quaife, Sara Upperton, Bethany Shinkins, Puvan Tharmanathan, Matthew E. J. Callister
Summary: Telephone risk assessment followed by a community-based LHC is an effective strategy for lung cancer screening implementation. However, lower participation associated with current smoking status and socioeconomic deprivation underlines the importance of research to ensure equitable access to screening.
EUROPEAN RESPIRATORY JOURNAL
(2022)
Article
Genetics & Heredity
Bethany Torr, Christopher Jones, Subin Choi, Sophie Allen, Grace Kavanaugh, Monica Hamill, Alice Garrett, Suzanne MacMahon, Lucy Loong, Alistair Reay, Lina Yuan, Mikel Valganon Petrizan, Kathryn Monson, Nicky Perry, Lesley Fallowfield, Valerie Jenkins, Rochelle Gold, Amy Taylor, Rhian Gabe, Jennifer Wiggins, Anneke Lucassen, Ranjit Manchanda, Ashu Gandhi, Angela George, Michael Hubank, Zoe Kemp, D. Gareth Evans, Stephen Bremner, Clare Turnbull
Summary: This study introduces a rapid digital pathway for genetic testing in breast cancer patients, which improves the uptake of testing with the support of clinicians and a genetics specialist hotline. The results demonstrate high satisfaction and similar outcomes for both the fully digital and partially digital pathways.
JOURNAL OF MEDICAL GENETICS
(2022)
Article
Oncology
Akifumi Hagiwara, Jacob Schlossman, Soroush Shabani, Catalina Raymond, Hiroyuki Tatekawa, Lauren E. Abrey, Josep Garcia, Olivier Chinot, Frank Saran, Ryo Nishikawa, Roger Henriksson, Warren P. Mason, Wolfgang Wick, Timothy F. Cloughesy, Benjamin M. Ellingson
Summary: Purpose Pseudoprogression (PsP) is a clinically important yet ill-defined phenomenon characterized by early radiographic progression followed by stability or regression. In this study, analysis of data from a control arm of a clinical trial in newly-diagnosed glioblastoma revealed distinct clinical, molecular, and MRI characteristics in patients with early progressive disease who eventually exhibited clinically-defined PsP. The radiomic analysis also showed promising accuracy in predicting PsP in these patients, providing valuable insights for treating clinicians.
JOURNAL OF NEURO-ONCOLOGY
(2022)
Article
Oncology
Lennard Y. W. Lee, Michael Tilby, Thomas Starkey, Maria C. Ionescu, Alex Burnett, Rosie Hattersley, Sam Khan, Martin Little, Justin K. H. Liu, James R. Platt, Arvind Tripathy, Isabella Watts, Sophie Therese Williams, Nathan Appanna, Youssra Al-Hajji, Matthew Barnard, Liza Benny, Andrew Buckley, Emma Cattell, Vinton Cheng, James Clark, Leonie Eastlake, Kate Gerrand, Qamar Ghafoor, Simon Grumett, Catherine Harper-Wynne, Rachel Kahn, Alvin J. X. Lee, Anna Lydon, Hayley McKenzie, Hari Panneerselvam, Jennifer Pascoe, Grisma Patel, Vijay Patel, Vanessa Potter, Amelia Randle, Anne S. Rigg, Tim Robinson, Rebecca Roylance, Tom Roques, Stefan Rozmanowski, Rene L. Roux, Ketan Shah, Martin Sintler, Harriet Taylor, Tania Tillett, Mark Tuthill, Sarah Williams, Andrew Beggs, Tim Iveson, Siow Ming Lee, Gary Middleton, Mark Middleton, Andrew S. Protheroe, Matthew W. Fittall, Tom Fowler, Peter Johnson
Summary: Accurate identification of patient groups with the lowest level of protection following COVID-19 vaccination is important. This study aims to evaluate the association between spike protein antibody vaccine response and the risk of SARS-CoV-2 breakthrough infection or hospitalization among patients with cancer.
Article
Oncology
Samuel Oxley, Ashwin Kalra, Michail Sideris, Nicole Itzkowitz, Olivia Evans, Emma Christine Atakpa, Adam R. Brentnall, Nina Dworschak, Faiza Gaba, Rhian Gabe, Sudha Sundar, Nick Wood, Shibani Nicum, Alexandra Taylor, Stephen Dobbs, W. Glenn McCluggage, Andy Nordin, Rosa Legood, Sean Kehoe, Sadaf Ghaem-Maghami, Ranjit Manchanda
Summary: This study examines the impact of multiple COVID-19 waves on gynaecological cancer services in the UK. Surveys were conducted after each wave, revealing a significant reduction in referrals, staffing shortages, and postponed surgeries during the first wave. Subsequent waves saw improvements in the number of referrals and staffing, but persistent staff shortages remained in 2022. The study highlights the need for adaptations in healthcare practices due to COVID-19.
Article
Respiratory System
Sara Upperton, Paul Beirne, Bobby Bhartia, Alison Boland, Claire Bradley, Philip A. J. Crosbie, Mike Darby, Claire Eckert, Rhian Gabe, Neil Hancock, Martyn P. T. Kennedy, Jason Lindop, Suzanne Rogerson, Bethany Shinkins, Irene Simmonds, Tim J. T. Sutherland, Matthew E. J. Callister
Summary: Interstitial lung abnormalities (ILA) are commonly found in low-dose CT screening for lung cancer, some of which are benign while others are associated with interstitial lung disease (ILD). A study on the prevalence and outcomes of ILA in a screening trial is reported, providing valuable insights for the management of screen-detected ILD.
BMJ OPEN RESPIRATORY RESEARCH
(2023)
Article
Respiratory System
Claire Bradley, Panos Alexandris, David R. Baldwin, Richard Booton, Mike Darby, Claire J. Eckert, Rhian Gabe, Neil Hancock, Sam Janes, Martyn Kennedy, Jason Lindop, Richard D. Neal, Suzanne Rogerson, Bethany Shinkins, Irene Simmonds, Sara Upperton, Jorgen Vestbo, Philip A. J. Crosbie, Matthew E. J. Callister
Summary: Spirometry offered alongside LDCT screening can potentially identify cases of undiagnosed and misdiagnosed COPD. Future research should assess the downstream impact of these findings and determine the impact of co-delivering spirometry on other parameters of LDCT screening.
Article
Oncology
Georgia K. B. Halkett, Lauren J. Breen, Melissa Berg, Rebecca Sampson, Hao-Wen Sim, Hui K. Gan, Benjamin Y. Kong, Anna K. Nowak, Bryan W. Day, Rosemary Harrup, Melissa James, Frank Saran, Brett Mcfarlane, Chris Tse, Eng-Siew Koh
Summary: The aim of this study was to identify research priorities, barriers, and enablers for adult primary brain tumour research in Australia and New Zealand. Through a two-phase modified Delphi study, key research topics, barriers, and enablers were identified. The top research priorities were focused on tumour biology, pre-clinical research, clinical and translational research, and supportive care. The top barriers included issues related to funding and resources, accessibility and awareness of research, collaboration, and process. The top enablers were funding and resources, collaboration, and workforce.